Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Business Wire•15/10/2026•08:05 ET
0
Key Highlights
- ➤Shield modeling projected 12 CRC deaths averted per 1,000 individuals, versus 6 for FIT and 9 for mt-sDNA
- ➤Shield modeling projected 679 colonoscopies per 1,000 individuals, versus 113 for FIT and 326 for mt-sDNA
- ➤Shield achieved 99% real-world adherence in two rural South Carolina health clinics
- ➤Shield has surpassed 200,000 real-world tests with over 90% screening adherence
- ➤Guardant Health (GH) presented the data at the ACG 2026 Annual Meeting
Expert Statements
Sam Asgarian, VP of Clinical Affairs at Guardant Health
“Today’s research continues to reinforce the data we’ve seen across Guardant’s robust real-world evidence: blood-based screening meaningfully closes gaps in colorectal cancer screening participation with a significant lift in underserved communities that face some of the most persistent access barriers.”
Sam Asgarian, VP of Clinical Affairs at Guardant Health
“For the first time, we’ve been able to correlate the impact of real-world follow-up colonoscopies and screening adherence with the modeling studies of the Shield blood test.”
Sam Asgarian, VP of Clinical Affairs at Guardant Health
“We’re proud to present this compelling research with our collaborators at ACG and to continue to demonstrate Shield’s role as a clinically meaningful alternative to traditional screening methods.”
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
* Modeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing
Get started
Create a free account to read the full story.